Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-Glu-L-Trp is a synthetic dipeptide composed of L-glutamic acid and L-tryptophan joined by a peptide bond. It is also known by the code name EW and the brand name Timogen. The compound is typically formulated as a white powder, soluble in water and DMF, and is insoluble in chloroform and ether. It has been investigated as a pharmaceutical agent with immunomodulatory properties, and preclinical studies indicate that it is not toxic even at high doses. L-Glu-L-Trp may act on the immune system, but its precise molecular mechanism of action is not fully elucidated. It is administered intramuscularly, intravenously, or intranasally[5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-Glu-L-Trp.